vs

Side-by-side financial comparison of Camden Property Trust (CPT) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.

Relay Therapeutics, Inc. is the larger business by last-quarter revenue ($7.0M vs $5.3M, roughly 1.3× Camden Property Trust).

Camden Property Trust is a publicly traded real estate investment trust that invests in apartments in the United States. As of December 31, 2023, the company owned interests in 176 apartment communities containing 59,800 apartment homes in the United States. It is the 14th largest owner of apartments in the United States.

Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.

CPT vs RLAY — Head-to-Head

Bigger by revenue
RLAY
RLAY
1.3× larger
RLAY
$7.0M
$5.3M
CPT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPT
CPT
RLAY
RLAY
Revenue
$5.3M
$7.0M
Net Profit
$156.0M
Gross Margin
Operating Margin
Net Margin
2954.1%
Revenue YoY
243.0%
Net Profit YoY
283.5%
EPS (diluted)
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPT
CPT
RLAY
RLAY
Q4 25
$5.3M
$7.0M
Q3 25
$2.6M
$0
Q2 25
$2.6M
Q1 25
$2.5M
$7.7M
Q4 24
$1.5M
$0
Q3 24
$1.7M
$0
Q2 24
$2.6M
$0
Q1 24
$1.3M
$10.0M
Net Profit
CPT
CPT
RLAY
RLAY
Q4 25
$156.0M
Q3 25
$108.9M
$-74.1M
Q2 25
$80.7M
Q1 25
$38.8M
$-77.1M
Q4 24
$40.7M
Q3 24
$-4.2M
$-88.1M
Q2 24
$42.9M
$-92.2M
Q1 24
$83.9M
$-81.4M
Operating Margin
CPT
CPT
RLAY
RLAY
Q4 25
Q3 25
Q2 25
Q1 25
-1105.2%
Q4 24
Q3 24
Q2 24
Q1 24
-903.0%
Net Margin
CPT
CPT
RLAY
RLAY
Q4 25
2954.1%
Q3 25
4246.9%
Q2 25
3063.8%
Q1 25
1561.0%
-1003.6%
Q4 24
2642.3%
Q3 24
-246.3%
Q2 24
1646.9%
Q1 24
6533.4%
-813.3%
EPS (diluted)
CPT
CPT
RLAY
RLAY
Q4 25
$1.44
Q3 25
$1.00
$-0.43
Q2 25
$0.74
Q1 25
$0.36
$-0.46
Q4 24
$0.37
Q3 24
$-0.04
$-0.63
Q2 24
$0.40
$-0.69
Q1 24
$0.77
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPT
CPT
RLAY
RLAY
Cash + ST InvestmentsLiquidity on hand
$25.2M
$84.0M
Total DebtLower is stronger
$3.9B
Stockholders' EquityBook value
$4.4B
$567.1M
Total Assets
$9.0B
$621.3M
Debt / EquityLower = less leverage
0.89×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPT
CPT
RLAY
RLAY
Q4 25
$25.2M
$84.0M
Q3 25
$25.9M
$91.6M
Q2 25
$33.1M
Q1 25
$26.2M
$93.5M
Q4 24
$21.0M
$124.3M
Q3 24
$31.2M
$152.4M
Q2 24
$93.9M
$134.1M
Q1 24
$92.7M
$152.9M
Total Debt
CPT
CPT
RLAY
RLAY
Q4 25
$3.9B
Q3 25
$3.7B
Q2 25
$3.8B
Q1 25
$3.7B
Q4 24
$3.5B
Q3 24
$3.5B
Q2 24
$3.6B
Q1 24
$3.6B
Stockholders' Equity
CPT
CPT
RLAY
RLAY
Q4 25
$4.4B
$567.1M
Q3 25
$4.5B
$607.7M
Q2 25
$4.6B
Q1 25
$4.6B
$721.1M
Q4 24
$4.7B
$777.8M
Q3 24
$4.7B
$838.9M
Q2 24
$4.9B
$681.7M
Q1 24
$4.9B
$745.8M
Total Assets
CPT
CPT
RLAY
RLAY
Q4 25
$9.0B
$621.3M
Q3 25
$9.1B
$670.0M
Q2 25
$9.1B
Q1 25
$9.0B
$799.4M
Q4 24
$8.9B
$871.3M
Q3 24
$8.9B
$930.1M
Q2 24
$9.1B
$772.5M
Q1 24
$9.1B
$841.4M
Debt / Equity
CPT
CPT
RLAY
RLAY
Q4 25
0.89×
Q3 25
0.82×
Q2 25
0.83×
Q1 25
0.81×
Q4 24
0.75×
Q3 24
0.73×
Q2 24
0.73×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPT
CPT
RLAY
RLAY
Operating Cash FlowLast quarter
$826.6M
$-235.5M
Free Cash FlowOCF − Capex
$-235.9M
FCF MarginFCF / Revenue
-3370.0%
Capex IntensityCapex / Revenue
5.9%
Cash ConversionOCF / Net Profit
5.30×
TTM Free Cash FlowTrailing 4 quarters
$-622.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPT
CPT
RLAY
RLAY
Q4 25
$826.6M
$-235.5M
Q3 25
$250.9M
$-62.1M
Q2 25
$230.7M
Q1 25
$148.2M
$-73.2M
Q4 24
$774.9M
$-249.1M
Q3 24
$261.6M
$-75.1M
Q2 24
$225.1M
$-65.8M
Q1 24
$135.9M
$-50.3M
Free Cash Flow
CPT
CPT
RLAY
RLAY
Q4 25
$-235.9M
Q3 25
$-62.1M
Q2 25
Q1 25
$-73.6M
Q4 24
$-251.1M
Q3 24
$-75.3M
Q2 24
$-65.8M
Q1 24
$-52.1M
FCF Margin
CPT
CPT
RLAY
RLAY
Q4 25
-3370.0%
Q3 25
Q2 25
Q1 25
-958.4%
Q4 24
Q3 24
Q2 24
Q1 24
-520.7%
Capex Intensity
CPT
CPT
RLAY
RLAY
Q4 25
5.9%
Q3 25
Q2 25
Q1 25
5.0%
Q4 24
Q3 24
Q2 24
Q1 24
17.8%
Cash Conversion
CPT
CPT
RLAY
RLAY
Q4 25
5.30×
Q3 25
2.30×
Q2 25
2.86×
Q1 25
3.82×
Q4 24
19.04×
Q3 24
Q2 24
5.24×
Q1 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons